title: Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.
abstract: OBJECTIVE
  CD8(+) CTLs have an essential role in immune response against tumor. Although tumor-associated antigens have been identified in renal cell carcinoma (RCC), few of these are commonly shared and investigated as therapeutic targets in the clinical medicine. In this report, we show that HIFPH3, a member of prolyl hydroxylases that function as oxygen sensor, is a novel tumor antigen and HIFPH3-specific CTLs are induced from peripheral blood lymphocytes of RCC patients.
  
  
  METHODS
  Expression of HIFPH3 was examined by reverse transcription-PCR and immunostaining with anti-HIFPH3 antibody. To identify HLA-A24-restricted T-cell epitopes of HIFPH3, eight peptides were selected from the amino acid sequence of this protein and screened for their binding affinity to HLA-A24. Peptide-specific CTLs were induced by stimulating peripheral blood lymphocytes of HLA-A24-positive RCC patients with these peptides in vitro. HLA-A24-restricted cytotoxicity of the CTLs against HIFPH3(+) RCC lines was assessed by chromium release assay.
  
  
  RESULTS
  HIFPH3 was overexpressed in many RCC cell lines and primary RCC tissues, whereas it was not detectable in normal adult tissues by reverse transcription-PCR. Of the eight peptides that contained HLA-A24-binding motif, HIFPH3-8 peptide (amino acid sequence, RYAMTVWYF) could induce the peptide-specific CTLs from 3 of 6 patients with HIFPH3-positive RCC. Furthermore, HIFPH3-8 peptide-specific CTLs showed cytotoxicity against HIFPH3(+) RCC cell lines in a HLA-A24-restricted manner.
  
  
  CONCLUSIONS
  HIFPH3 may be a target antigen in immunotherapy for RCC and HIFPH3-8 peptide could be used as a peptide vaccine for HLA-A*2402(+)/HIFPH3(+) RCC patients.
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
authors.forename: Eiji
authors.initials: E
authors.lastname: Sato
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Torigoe
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hirohashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitamura
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Ichiya
authors.initials: I
authors.lastname: Honma
authors.forename: Hiroko
authors.initials: H
authors.lastname: Asanuma
authors.forename: Kenji
authors.initials: K
authors.lastname: Harada
authors.forename: Hideo
authors.initials: H
authors.lastname: Takasu
authors.forename: Naoya
authors.initials: N
authors.lastname: Masumori
authors.forename: Naoki
authors.initials: N
authors.lastname: Ito
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000276:immunology*; D045744:Cell Line, Tumor; D049308:Dioxygenases / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte / Q000032:analysis*; D006801:Humans; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D007680:Kidney Neoplasms / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D018984:Epitopes, T-Lymphocyte; D049308:Dioxygenases; C488894:EGLN3 protein, human; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases